
Last updated: 2026-09-16 09:04:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Bio-Techne Corp. (TECH) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $72,27, with a market capitalisation of $11,33B and a P/E ratio of 62,38. Over the past 52 weeks, its price has ranged from $43,20 to $72,62. This page covers its latest market performance, valuation, price trends and company information.
$11,33B | |
$72,27 | |
$135,96 | |
$7,67 | |
$72,34 | |
27,00 | |
4,67M | |
62,38 | |
$72,62 | |
$43,20 | |
0,44% | |
-- |
Bio-Techne Corp. (TECH) is trading at $72,27 in pre-market trading as of 2026-09-16 08:11:00, down 0,10% ($0,07) from the previous close of $72,34
Pre-market trading shows how investors are pricing TECH before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Bio-Techne Corp. (TECH) moved from $72,43 to $72,27, representing a decline of 0,22% ($0,16).
The stock traded between $72,08 and $72,48 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 2,59 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 98,8%
TECH is currently trading at $72,27, placing it 98,8% of the way from its 52-week low of $43,20 to its 52-week high of $72,62. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 3000 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Bio-Techne Corp. (TECH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.